– UK, London – Smith+Nephew (LON: SN | NYSE: SNN), the global medical technology business, today announced the appointment of Katarzyna Mazur-Hofsaess to its Board as a Non-Executive Director, effective on 1st November 2020.
“We are delighted to have secured Katarzyna as a Non-Executive Director. Her deep industry knowledge, senior leadership experience and medical background make her an excellent addition to the Board team.” said Board Chair, Roberto Quarta.
About Katarzyna Mazur-Hofsaess
Katarzyna has a strong track record in senior leadership within the MedTech industry and is a qualified medical doctor.
Since 2017 Katarzyna has served as CEO for the €2.7 billion EMEA business of Fresenius Medical Care AG & Co. KGaA, the German-listed renal care company. Previously she spent eight years at Zimmer Biomet (previously Zimmer) as President, EMEA, and held leadership roles at Abbott Laboratories, Allergy Therapeutics and Roche.
Katarzyna qualified as a doctor from the Medical University of Gdańsk, Poland in 1987 and completed an Executive MBA at the University of Minnesota, US, in 2002. Katarzyna is a Polish and German national.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100.
For more information: https://www.smith-nephew.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.